Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%
March 4 (Reuters) - Formosa Pharmaceuticals Inc:
* FORMOSA PHARMACEUTICALS AND AIMMAX THERAPEUTICS RECEIVE
FDA
APPROVAL FOR CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION 0.05%,
FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN
FOLLOWING OCULAR SURGERY
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyperion DeFi
See all newsHyperion DeFi Inc reports results for the quarter ended September 30 - Earnings Summary
Hyperion DeFi posts third straight record quarterly profit
Hyperion DeFi Inc expected to post earnings of $1.81 a share - Earnings Preview
Brief: Hyperion Defi Raises Guidance And Announces $20M Share Repurchase Program
Hyperion DeFi Inc reports results for the quarter ended June 30 - Earnings Summary